SCHOTT Pharma stock (DE000A3ENQ51): valuation back in focus as Xetra price edges above EUR 18

SCHOTT Pharma shares showed a firmer tone on the German home market on 05/29/2026, with the stock trading above EUR 18 on Xetra and putting the company’s valuation profile back in the spotlight for local investors, according to finanzen.net as of 05/29/2026.

In midday Xetra trading on 05/29/2026, SCHOTT Pharma changed hands at around EUR 18.14, up roughly 0.9 percent on the day, while the intraday high reached EUR 18.24, based on data from finanzen.ch as of 05/29/2026 and finanzen.net as of 05/29/2026.

The stock traded at about EUR 18.14 on 05/29/2026 on Xetra, according to finanzen.ch as of 05/29/2026.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

SCHOTT Pharma: core business model

SCHOTT Pharma focuses on specialized containment and drug delivery solutions for injectable medicines, generating revenue mainly from supplying high-value vials, syringes and related systems to pharmaceutical and biotech customers worldwide.

Valuation metrics and multiples for SCHOTT Pharma

With the share price hovering a little above EUR 18 on 05/29/2026, SCHOTT Pharma’s equity valuation continues to be closely watched on the German market, particularly given its role as a focused pharma packaging and drug delivery supplier.

Market observers often compare the company’s earnings and cash flow multiples with those of other listed drug-packaging specialists, although detailed current P/E and EV/EBITDA figures were not disclosed in the latest intraday trading commentary from ad-hoc-news.de as of 05/29/2026.

Conclusion

The move in SCHOTT Pharma shares above EUR 18 on Xetra on 05/29/2026 keeps the company’s valuation and trading dynamics squarely in focus for investors in Germany. With the company positioned in the specialized market for injectable drug containment and delivery, the stock’s pricing remains closely tied to expectations for pharma and biotech demand. How valuation multiples develop from here will depend on future financial disclosures and the broader sentiment toward healthcare-related industrial suppliers.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.